ATE499094T1 - Zusammensetzungen mit vitamin k zur prävention von bluthochdruck, linksherzhypertrophie, kongestive herzinsuffizienz, myocardinfarkt, schlaganfall und koronarer herzkrankheitend durch prävention von altersbedingter versteifung von arterien - Google Patents

Zusammensetzungen mit vitamin k zur prävention von bluthochdruck, linksherzhypertrophie, kongestive herzinsuffizienz, myocardinfarkt, schlaganfall und koronarer herzkrankheitend durch prävention von altersbedingter versteifung von arterien

Info

Publication number
ATE499094T1
ATE499094T1 AT03790959T AT03790959T ATE499094T1 AT E499094 T1 ATE499094 T1 AT E499094T1 AT 03790959 T AT03790959 T AT 03790959T AT 03790959 T AT03790959 T AT 03790959T AT E499094 T1 ATE499094 T1 AT E499094T1
Authority
AT
Austria
Prior art keywords
vitamin
arteries
hypertension
stroke
myocardial infarction
Prior art date
Application number
AT03790959T
Other languages
English (en)
Inventor
Cees Vermeer
Original Assignee
Nattopharma Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9943229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE499094(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nattopharma Asa filed Critical Nattopharma Asa
Application granted granted Critical
Publication of ATE499094T1 publication Critical patent/ATE499094T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03790959T 2002-08-30 2003-09-01 Zusammensetzungen mit vitamin k zur prävention von bluthochdruck, linksherzhypertrophie, kongestive herzinsuffizienz, myocardinfarkt, schlaganfall und koronarer herzkrankheitend durch prävention von altersbedingter versteifung von arterien ATE499094T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0220182.0A GB0220182D0 (en) 2002-08-30 2002-08-30 Organic compounds
PCT/EP2003/009746 WO2004019923A1 (en) 2002-08-30 2003-09-01 Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries

Publications (1)

Publication Number Publication Date
ATE499094T1 true ATE499094T1 (de) 2011-03-15

Family

ID=9943229

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03790959T ATE499094T1 (de) 2002-08-30 2003-09-01 Zusammensetzungen mit vitamin k zur prävention von bluthochdruck, linksherzhypertrophie, kongestive herzinsuffizienz, myocardinfarkt, schlaganfall und koronarer herzkrankheitend durch prävention von altersbedingter versteifung von arterien

Country Status (11)

Country Link
US (3) US20060166948A1 (de)
EP (1) EP1556025B1 (de)
AT (1) ATE499094T1 (de)
AU (1) AU2003264150A1 (de)
DE (1) DE60336161D1 (de)
DK (1) DK1556025T3 (de)
ES (1) ES2361740T3 (de)
GB (1) GB0220182D0 (de)
PT (1) PT1556025E (de)
SI (1) SI1556025T1 (de)
WO (1) WO2004019923A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20060191026A1 (en) 2005-02-18 2006-08-24 Origen Therapeutics, Inc. Tissue specific expression of antibodies in chickens
WO2005011660A1 (en) * 2003-07-29 2005-02-10 Abbott Laboratories Use of vitamin d to down regulate the renin-angiotensin-aldosterone system
US8685374B2 (en) * 2003-09-12 2014-04-01 Ray And Terry's Health Products, Inc. EDTA containing compositions and uses thereof
BE1016566A4 (fr) * 2004-05-25 2007-02-06 Psaltopoulos Emmanuel Procede pour fournir les besoins quotidiens de l'etre humain en calcium (ca), en vitamine "d" et en vitamine "k" sous forme de pilule a croquer ou a avaler.
WO2006113479A2 (en) 2005-04-15 2006-10-26 Albert Einstein College Of Medicine Of Yeshiva University Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy
SI1728507T1 (sl) * 2005-06-03 2011-07-29 Nattopharma Asa Uporaba vitamina K za reverziranje kalcifikacije krvnih Ĺľil
US9125732B2 (en) 2005-07-25 2015-09-08 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US8923972B2 (en) 2005-07-25 2014-12-30 Vascular Dynamics, Inc. Elliptical element for blood pressure reduction
US9592136B2 (en) 2005-07-25 2017-03-14 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US9125567B2 (en) 2005-07-25 2015-09-08 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US9642726B2 (en) 2005-07-25 2017-05-09 Vascular Dynamics, Inc. Devices and methods for control of blood pressure
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
WO2007033083A2 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (dmso) or related compounds, or odors associated with same
EP1937286B1 (de) 2005-09-12 2016-03-09 Abela Pharmaceuticals, Inc. Zusammensetzungen aus dimethylsulfoxid (dmso)
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
ITRM20050521A1 (it) * 2005-10-21 2007-04-22 Opocrin Spa Composizione a base di vitamine k e d per la prevenzione e il trattamento dell'osteoporosi.
CA2656613A1 (en) 2006-07-03 2008-01-10 Genmab A/S Prevention of rash in patients undergoing anti-egfr therapy
CA2657748C (en) * 2006-07-14 2014-10-21 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2
US10716798B2 (en) 2007-02-21 2020-07-21 The Regents Of The University Of Michigan Compositions and methods for tranquilizing heart muscle
FR2916354B1 (fr) * 2007-05-25 2009-08-07 Univ Picardie Jules Verne Etab Composition pharmaceutique pour inhiber la calcification vasculaire.
GB0710439D0 (en) * 2007-05-31 2007-07-11 Uni I Oslo Oral dosage form
US20090053366A1 (en) * 2007-08-21 2009-02-26 Marni Markell Hurwitz Refreshment system having effervescent supplement tablets
WO2009108297A2 (en) * 2008-02-25 2009-09-03 Nephrian, Inc. Combination therapy for treatment of bone and mineral disorders for patients with impaired renal function
US20100331286A1 (en) * 2008-02-25 2010-12-30 Ray Chow Combination therapy for treatment of bone and mineral disorders for patients with impaired renal function
US8815953B2 (en) 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
FR2949044B1 (fr) 2009-08-12 2021-05-07 Expanscience Lab Composition comprenant une fraction d'insaponifiable
US9855212B2 (en) 2009-10-30 2018-01-02 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases
US9333228B2 (en) * 2010-06-01 2016-05-10 Top Doctors Labs, Llc Nutritional supplement for recovery, repair, and maintenance
WO2012059942A2 (en) * 2010-11-01 2012-05-10 Viridis Biopharma Pvt. Ltd Dynamic balancing of autonomic nervous system through vitamin mk-7
NZ613264A (en) * 2010-12-17 2015-05-29 Vitak Bv Use of vitamin k for weight maintenance and weight control
US8815310B2 (en) * 2011-01-10 2014-08-26 Morteza Naghavi Compositions for boosting metabolism, assisting weight loss, and promoting cardiovascular health
WO2012142474A2 (en) 2011-04-13 2012-10-18 Thermolife International, Llc N-acetyl beta alanine methods of use
NL2008294C2 (en) * 2011-05-20 2013-08-19 Friesland Brands Bv Food composition comprising vitamin k and saturated fat.
EP2709460A1 (de) * 2011-05-20 2014-03-26 Friesland Brands B.V. Zusammensetzung mit vitamin k2
WO2014191466A1 (en) * 2013-05-28 2014-12-04 Nattopharma Asa Menaquinone supplementation and vascular health
EP2886129A1 (de) * 2013-12-20 2015-06-24 VitaK B.V. Prävention und Gegenaktion von diätinduzierter Thrombosegefahr
ITPD20140287A1 (it) * 2014-10-30 2016-04-30 Fusaro Maria K-pharma
US11344575B2 (en) 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
US11357250B2 (en) 2016-08-15 2022-06-14 Summit Innovation Labs LLC Treatment and prevention of diabetes and obesity
IT201700085412A1 (it) * 2017-07-26 2019-01-26 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
WO2019191773A1 (en) * 2018-03-30 2019-10-03 Kaydence Pharma As Rapidly improving vascular conditions by administering vitamin k
CA3133054A1 (en) * 2019-03-11 2020-09-17 Kaydence Pharma As Rapidly improving endothelial function, reducing arterial stiffness and reversing calcification of blood vessels by administering vitamin k
CN110122866A (zh) * 2019-05-31 2019-08-16 广东双骏生物科技有限公司 一种慢性肾脏病血管钙化的特殊医学用途食品及制备方法
WO2022072663A1 (en) * 2020-10-01 2022-04-07 Emergent Product Development Gaithersburg Inc. Stabilized alkyl nitrite compositions
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
US20230060177A1 (en) * 2021-08-19 2023-03-02 Imam Abdulrahman Bin Faisal University Method for treating athletes subject to pathological cardiac hypertrophy by administering nigella sativa

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3949098A (en) * 1974-06-05 1976-04-06 Nabisco, Inc. Nutritious orange drink concentrate, process and drink resultant therefrom
GB8523338D0 (en) * 1985-09-20 1985-10-23 Kreitzman S N Treatment of obesity
US5180747A (en) * 1989-02-28 1993-01-19 Nisshin Flour Milling Co., Ltd. Stabilized fat-soluble vitamin compositions
JPH06312950A (ja) * 1993-03-01 1994-11-08 Eezai Kagaku Kk キノン誘導体の製造法および中間体
US5590649A (en) * 1994-04-15 1997-01-07 Vital Insite, Inc. Apparatus and method for measuring an induced perturbation to determine blood pressure
JP3860849B2 (ja) * 1994-04-28 2006-12-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗動脈硬化治療剤
EP0679394B1 (de) 1994-04-28 1998-01-14 Eisai Co., Ltd. Hematetrenome Derivat als antiarteriosklerotisches Mittel
GB9600604D0 (en) * 1996-01-12 1996-03-13 Boots Co Plc Composition
GB9713620D0 (en) 1997-06-28 1997-09-03 Boots Co Plc Composition
US6093425A (en) * 1997-11-21 2000-07-25 Princeton Nutrition, L.L.C. Complete nutritional milk compositions and products
US6914073B2 (en) * 1999-03-18 2005-07-05 Bristol Myers Squibb Company Vitamin formulation for cardiovascular health
KR20020016833A (ko) * 1999-06-15 2002-03-06 뉴트리-로직스, 인크. 발병 감소에 유용한 영양 제제, 관련 치료 방법 및 성분스크리닝 방법
DE19955607A1 (de) * 1999-11-19 2001-06-07 November Ag Molekulare Medizin Medikament oder aufeinander abgestimmte Kombination von Medikamenten
EP1153548B8 (de) * 2000-05-12 2007-06-27 NattoPharma ASA Nahrungsmittel enthaltend Vitamin k2
GB0016452D0 (en) * 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
US20020016372A1 (en) * 2000-07-31 2002-02-07 Allison Anthony Clifford Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury
WO2003013420A2 (en) 2001-08-03 2003-02-20 Vitak Bv Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification
SI1728507T1 (sl) 2005-06-03 2011-07-29 Nattopharma Asa Uporaba vitamina K za reverziranje kalcifikacije krvnih Ĺľil

Also Published As

Publication number Publication date
AU2003264150A1 (en) 2004-03-19
EP1556025A1 (de) 2005-07-27
US20050261257A1 (en) 2005-11-24
EP1556025B1 (de) 2011-02-23
US9364447B2 (en) 2016-06-14
WO2004019923A1 (en) 2004-03-11
ES2361740T3 (es) 2011-06-21
DK1556025T3 (da) 2011-05-23
US20060166948A1 (en) 2006-07-27
SI1556025T1 (sl) 2011-07-29
DE60336161D1 (de) 2011-04-07
PT1556025E (pt) 2011-05-11
US20160250160A1 (en) 2016-09-01
GB0220182D0 (en) 2002-10-09

Similar Documents

Publication Publication Date Title
ATE499094T1 (de) Zusammensetzungen mit vitamin k zur prävention von bluthochdruck, linksherzhypertrophie, kongestive herzinsuffizienz, myocardinfarkt, schlaganfall und koronarer herzkrankheitend durch prävention von altersbedingter versteifung von arterien
DK1728507T3 (da) Anvendelse af vitamin K for at omvende forkalkning af blodkar
Fukui et al. Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris
Ennabli et al. Morbidity and mortality of coronary artery surgery after the age of 70 years
DK1532269T3 (da) 1L1RL-1 som markør for kardiovaskulær sygdom
JP2015512387A5 (de)
IL166493A0 (en) Acylamino-substituted heteroaromatic compounds andtheir use as pharmaceuticals
DE60141849D1 (de) Pharmazeutisch aktive sulfonamid-derivate
BR0015561A (pt) Produto alimentìcio
WO2003015695B1 (en) Canine cardiac diet
WO2007089787A3 (en) Compositions and methods for treating cardiovascular, cerebrovascular and other vascular disease patients
FI3562487T3 (fi) Metalloentsyymi-inhibiittoriyhdisteitä
Tio et al. Ventricular septal rupture caused by myocardial bridging
Ceyhan et al. Myocardial infarction following a bee sting
Rocchini et al. Left ventricular function following attempted surgical repair of tetralogy of Fallot.
Papazoglou et al. Left anterior descending coronary artery–left ventricular fistula presenting as unstable angina and syncope
Prasad et al. Modified supra-arterial myotomy for intermittent coronary obstruction by myocardial bridges
CA2329232A1 (en) Stable compositions comprising levosimendan and alginic acid
JP2017530954A5 (de)
Isomatsu et al. Left atrial myxoma associated with acute myocardial infarction
Guo et al. Coronary artery spasm: a rare but important cause of postoperative myocardial infarction
Moreno-Franco et al. Soluble and insoluble dietary fibre intake and risk factors for cvd and metabolic syndrome in middle-aged adults: The AWHS cohort
Çağlar et al. Coexistence of Ectasia and Myocardial Bridge on the Same Coronary Artery Segment.
D'Attellis et al. A shocking injury
DK0966455T3 (da) Oxirancarboxylsyrer til behandling af diabetes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1556025

Country of ref document: EP